Innovations are created to solve the limitations of an
|
|
- Maude Green
- 5 years ago
- Views:
Transcription
1 Sponsored by Lutonix, Inc. Defining the Next Generation of Drug-Coated Balloon Technology BY KEN ROSENFIELD, MD, AND STEPHAN DUDA, MD Innovations are created to solve the limitations of an existing technology or approach. In the endovascular arena, bare-metal stents were designed to combat the elastic recoil and restenosis that can limit the effectiveness of plain balloon angioplasty, antiplatelet therapy was modified to minimize the risk of stent thrombosis after stenting, and drug-eluting stents (DES) were developed to curtail the neointimal hyperplasia and late loss that are responsible for unacceptable restenosis rates with bare-metal stents. Most recently, drug-coated balloon (DCB) technology has been developed as an alternative to address the limitations of existing therapeutic approaches to coronary and peripheral arterial disease. Compared with DES and other existing therapeutic approaches, DCBs offer several potential advantages, including targeted drug release without the use of a polymer, a degree of homogeneous drug delivery to the vessel wall that is not achieved with DES, and a shortened duration of antiplatelet therapy. 1,2 In addition, DCBs may treat vascular lesions that are not well served by stents, such as high flexion sites, small vessels, long lesions, and bifurcation stenoses. The use of stents for the percutaneous treatment of peripheral vascular disease can be limited by the occurrence of stent fracture, high restenosis rates, and anatomical challenges. Likewise, in coronary artery stenting, there remain significant clinical challenges, including in-stent restenosis, delivery of devices through calcified or tortuous anatomy, obstruction of side branches in bifurcation lesions, and management of small-vessel disease. Preclinical and clinical data suggest that DCBs may play an important role in addressing these challenges by delivering local antiproliferative agents to the vasculature without implantation of a foreign body (ie, a stent) or the need for long-term dual-antiplatelet therapy. With DES, as in the early years of any new technology, extensive preclinical and clinical research and product development were undertaken to refine the first-generation technologies, weed out the poor performers, and, ultimately, develop the DES that are widely used today. Like those early stages of DES development, DCB technology is currently in its infancy and is just beginning its journey through the iterative scientific process that can yield a robust, clinically validated technology to address some of the remaining challenges in treating atherosclerotic disease. THE HISTORY OF DCB DEVELOPMENT Through a series of cell culture experiments, Scheller and colleagues determined that short-duration exposure ( 3 min) to paclitaxel admixed to the contrast medium, iopromide, produced long-term inhibition of cellular proliferation of vascular smooth muscle cells. 3 In subsequent studies using the porcine coronary overstretch model, the same group demonstrated that short-duration exposure to paclitaxel, either dissolved in iopromide or coated onto a balloon catheter with iopromide, is sufficient to inhibit cell proliferation and neointimal hyperplasia. 3-6 In Europe, four DCB technologies have been introduced for coronary interventions, as well as three for peripheral interventions, although none have yet been approved by the US Food and Drug Administration. These innovative DCB technologies were introduced with great promise but thus far have been adopted cautiously. This is likely due to somewhat inconsistent clinical results, which may be related to important differences among the devices. Initial coronary and peripheral outcomes have been largely positive, with a few exceptions. For example, randomized, controlled trials of the Paccocath DCB (B. Braun Interventional Systems Inc., Bethlehem, PA) for treating coronary in-stent stenosis have shown the superiority of DCBs over uncoated balloons, with signif- 26 I INSERT TO ENDOVASCULAR TODAY I SEPTEMBER 2010 Caution Investigational Device, Limited by Federal (USA) Law to Investigational Use. If you are interested in becoming an investigator in the Lutonix LEVANT II trial, please send an to research@lutonix.com.
2 A B Figure 1. Illustration of how the carrier controls drug loss during balloon transit to the treatment site (A) and drug uptake in treated tissues (B). icantly lower late lumen loss and fewer major adverse cardiac events. 7,8 These beneficial effects were maintained 2 years after intervention, in spite of only 4 weeks of postprocedure antiplatelet therapy (as opposed to 12-month or lifelong therapy for DES). 7,8 However, clinical and angiographic outcomes with some of the other DCB designs on the market have been less promising. 2 In peripheral vessels, the Paccocath DCB has been evaluated for treating stenosis or occlusion in the superficial femoral or popliteal arteries (THUNDER trial) and the femoropopliteal artery (FemPac trial). Compared with uncoated balloons, the use of DCBs in both studies resulted in a significant reduction in late lumen loss at 6 months and fewer target lesion revascularizations through 18 to 24 months postprocedure. 9,10 These encouraging early data have generated hope that DCBs might provide a compelling therapeutic answer to the pervasive challenge of achieving exceptional clinical outcomes for infrainguinal disease. The variability of performance among a new class of devices should not be disconcerting, or even surprising. In their recent editorial on DCBs, Gray and Granada point out that not all DCBs are the same and forecast that their construct will have implications for their clinical effectiveness. 1 Although the current generation of DCBs all use the antiproliferative agent paclitaxel, their delivery mechanisms and coating characteristics may differ substantially from one another and from some of the newer DCBs in development. CRITICAL ASPECTS OF DCB DESIGN In the case of DES, the coating matrix turned out to be at least as important as the chosen drug. 2 So too, the critical differences among DCBs relate to their formulations and, specifically, to the drug carrier used. In the Figure 2. Optimization of drug release from a drug carrier. With no carrier or a carrier that releases the drug too slowly, there is insufficient drug uptake in the vessel wall. With a suboptimal carrier that releases drug off the balloon too quickly during transit to the lesion, a higher dose is lost in the bloodstream, and drug delivery to the vessel wall is insufficient. early DCB experiments, Scheller noted that not all forms of a paclitaxel-coated balloons were similarly effective. 5 Further preclinical research has confirmed Scheller s initial observations. 1,2,11 Although all of the marketed devices thus far have used paclitaxel, all use different drug carriers, each of which can vary widely in its transfer efficiency. The drug carrier is of great importance because it governs several critical parameters affecting both safety and efficacy. These parameters include the total drug load required on the balloon, the durability and uniformity of the balloon coating drug dose, the relative uptake by the vessel wall, and the downstream drug dose. Drug retention during delivery to the therapeutic site is also an important variable. Figure 1A illustrates the impact that different carriers have on drug loss during balloon transit to the treatment site. For example, a carrier that allows a greater percentage of paclitaxel to be shed from the balloon during transit results in a SEPTEMBER 2010 I INSERT TO ENDOVASCULAR TODAY I 27
3 higher dose lost to downstream tissues and organs. Transfer efficiency of the carrier, another important parameter, determines the amount of drug actually delivered to the vessel wall. Figure 1B shows how a carrier with lower transfer efficiency results in less of the balloon s paclitaxel load successfully diffusing into the arterial wall. When using carriers that have either low drug retention during transit or low transfer efficiency, more paclitaxel must be loaded on the balloon to reach the targeted therapeutic dose. Of note, the carrier molecule is a necessary feature of DCBs; without it, the hydrophobic paclitaxel is retained on the balloon during transit through the bloodstream, but it does not transfer efficiently into the arterial wall. The ideal carrier is one that optimizes retention during transit and transfer during inflation. Figure 2 demonstrates the optimization of drug carrier characteristics in terms of drug retention during transit, the optimal rate of drug release at the treatment site, and adequate tissue levels of paclitaxel. Along with the drug carrier itself, the manufacturing process and resulting coating durability characteristics are critical factors in DCB design. For example, if coating particles flake off during balloon preparation or insertion into the valve, an undetermined amount of paclitaxel has been removed from the balloon, thereby making it difficult to ensure consistent dose levels to the arterial wall. It is also essential that the coating be robust enough to withstand intra-arterial conditions that can cause drug loss during transit, such as vessel tortuosity, heavy plaque burden, or calcification. These issues will be important for the developers of DCBs to investigate with rigorous bench and preclinical research. The uniformity and robustness of each balloon coating is dictated by both the specific formulation and the manufacturing methods, such as coating application. Some DCBs are coated while the balloon is deflated, whereas others, such as the Moxy Drug-Coated Balloon Catheter (Lutonix, Inc., Maple Grove, MN) (Figure 3), have the coating applied while the balloon is inflated, after which, the balloon is deflated and wrapped. The ideal DCB should meet several criteria. 1 Although the clinical impact of different coating methods is not yet clear, it is essential that the coating be robust enough to maintain the drug on the balloon during transit to the treatment site. The drug carrier should rapidly and efficiently deliver a therapeutic dose to the vessel wall with the lowest possible drug load on the balloon to minimize the downstream drug effect. Even coating distribution on the balloon and an efficient drug carrier will also be important to optimize the delivery dose to the vessel wall. Finally, the technology should be supported by extensive, rigorous preclinical science using Figure 3. Close-up view of the Moxy balloon coating. Figure 4. The Moxy balloon is coated with paclitaxel and a proprietary drug carrier. the precise formulation and manufacturing processes as the clinically tested commercial product. NEXT-GENERATION DCB TECHNOLOGY The DCBs that have been introduced in Europe thus far share a number of characteristics in common all use paclitaxel, most are loaded with 3 µg/mm 2 of paclitaxel on the balloon, and all but one employ a drug carrier, although the choice of drug carrier varies from one device to another. To date, the carriers used include iopromide, urea, butyryl-trihexyl citrate, and shellolic acid. Future development efforts may encompass alternative antiproliferative agents, drug carriers, or both. 1 One new DCB that aims to improve on the first-generation technologies is the Moxy balloon (Figure 4). Rather than model their drug carrier after the existing compounds, the Moxy development process began with exploring the universe of possible carrier molecules in an effort to screen and optimize the coating formulation. The final formulation is a result of assessing more than 225 possible carriers and more than 250 possible formulations through more than 40 preclinical animal studies spanning pharmacokinetics to arterial dose distribution. The resulting proprietary formulation of paclitaxel plus a highly efficient drug carrier from the 28 I INSERT TO ENDOVASCULAR TODAY I SEPTEMBER 2010
4 A B Figure 5. The Moxy balloon delivers paclitaxel to the endoluminal surface during inflation (A). Over time, therapeutic drug levels are sustained in the deeper layers of the arterial wall but not in the endothelium (B), thereby allowing re-endothelialization. Figure 6. Angiogram of a 72-year-old man with Rutherford stage 2 peripheral artery disease and 80% stenosis in the proximal portion of the left superficial femoral artery. The lesion was predilated with a 5- X 40-mm Pacific Xtreme balloon (Medtronic Invatec, Frauenfeld, Switzerland) followed by a 1-minute dilatation with a 5- X 60-mm Moxy balloon for a postprocedure residual stenosis of 25%. At 6-month follow-up angiography, the patient presented with Rutherford stage 1 disease and a widely patent vessel. US Food and Drug Administration intravenousapproved list delivers the same therapeutic dose of paclitaxel to the vessel wall as the current DCBs on the European market, with a minimal amount of drug (2 µg/mm 2 ) loaded on the balloon. This proprietary carrier is stable, nonreactive, hydrophilic, water soluble, and has an affinity for paclitaxel. The evenly distributed, stable coating (Figure 3) is specifically designed to deliver a uniform dose to the vessel wall while minimizing downstream drug delivery. The mechanism by which a single application of antiproliferative drug inhibits restenosis for months to years remains uncertain, 1 and the rate of drug release and amount of tissue uptake will vary depending on the formulation used. Preclinical research and computational modeling show that the Moxy balloon lays down a paclitaxel reservoir from which the drug diffuses into the vessel wall over time. During balloon inflation, the paclitaxel and drug carrier are delivered to the endoluminal surface, where they remain after the balloon is deflated (Figure 5A). Paclitaxel gradually diffuses into the medial and adventitial layers from this reservoir. Over time, the paclitaxel dose levels become subtherapeutic at the endoluminal surface, but remain resident at therapeutic levels deeper in the arterial wall. Consequently, healthy endothelial cells are able to grow and reline the lumen while the deeper arterial layers continue to receive a sustained therapeutic dose (Figure 5B). Lutonix has completed three first-inman clinical studies, for which 6-month angiographic and clinical follow-up will be available later this year. In the peripheral arteries, the LEVANT I randomized trial (N = 101) is evaluating the Moxy balloon compared with an uncoated balloon for treating ischemic lesions in the superficial femoral and popliteal arteries. Angiograms from a patient in LEVANT I (Figure 6) show improvement from 80% stenosis in the proximal portion of the left superficial femoral artery at baseline to a residual stenosis of 25% postprocedure and a widely patent vessel during 6-month follow-up angiography. In the coronary arteries, the De Novo (N = 26) and PERVIDEO I (N = 41) single-arm studies are evaluating the Moxy balloon in de novo and in-stent restenosis lesions, respectively. SEPTEMBER 2010 I INSERT TO ENDOVASCULAR TODAY I 29
5 A BRIGHT FUTURE FOR DCB TECHNOLOGY Appreciating the potential of DCB technology requires a closer look at several factors: the clinical efficacy of each individual device, the specific drug carrier and coating formulation, and the appropriate clinical indications and techniques employed. DCBs may offer a valuable therapeutic alternative in situations in which the current therapies have proven unfeasible. In the coronary arteries, DES are suboptimal for in-stent restenosis lesions, small-vessel disease, and bifurcation lesions in which the stent can obstruct side branches. In the peripheral arteries, in which restenosis and stent fracture are concerns, DCBs may offer a much needed therapeutic option for femoral, popliteal, and belowthe-knee artery disease. Well-designed, randomized controlled clinical trials will be essential for elucidating the most appropriate clinical indications for DCBs. Acknowledgements: The authors wish to thank Laurie LaRusso, MS, ELS, for her contribution to the writing of this article. Ken Rosenfield, MD, is the Section Head for Vascular Medicine and Intervention within the Division of Cardiology at Massachusetts General Hospital in Boston, Massachusetts. He has disclosed that he receives grant/research funding from Lutonix, Inc. He has also disclosed that he is the coprincipal investigator of the LEV- ANT II Trial. Dr. Rosenfield can be reached at (617) ; krosenfield@fastmail.us. Stephan Duda, MD, is with the Jewish Hospital in Berlin, Germany. He has disclosed that he is a paid consultant to Cordis Corporation and receives grant/research funding from Lutonix, Inc. Dr. Duda may be reached at +49 (0) ; stephan.duda@ihre-radiologen.de. 1. Gray WA, Granada JF. Drug-coated balloons for the prevention of vascular restenosis. Circulation. 2010;121: Tepe G, Schmitmeier S, Speck U, et al. Advances on drug-coated balloons. J Cardiovasc Surg (Torino). 2010;51: Scheller B, Speck U, Schmitt A, et al. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol. 2003;42: Albrecht T, Speck U, Baier C, et al. Reduction of stenosis due to intimal hyperplasia after stent supported angioplasty of peripheral arteries by local administration of paclitaxel in swine. Invest Radiol. 2007;42: Scheller B, Speck U, Abramjuk C, et al. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;110: Scheller B, Speck U, Romeike B, et al. Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J. 2003;24: Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355: Scheller B, Hehrlein C, Bocksch W, et al. Two-year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol. 2008;97: Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358: Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118: Cremers B, Biedermann M, Mahnkopf D, et al. Comparison of two different paclitaxelcoated balloon catheters in the porcine coronary restenosis model. Clin Res Cardiol. 2009;98: I INSERT TO ENDOVASCULAR TODAY I SEPTEMBER 2010
Drug-coated balloons (DCBs) have been shown
Mechanisms of Action in Drug- Coated Balloons Insights into the clinical safety and efficacy of this emerging technology. By Maxwell E. Afari, MD, and Juan F. Granada, MD, FACC Drug-coated balloons (DCBs)
More informationDrug delivery to the vessel wall: Coated balloons and the role of the excipient
Drug delivery to the vessel wall: Coated balloons and the role of the excipient Nathan Lockwood BioInterface 2015 2015 SurModics, Inc. 1 Evolution of Devices & Therapy: POBA to DCB Balloon angioplasty
More informationDrug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND
Drug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND Drug eluting stents and balloons Endovascular treatment now becoming more popular for treatment
More informationTHE SCIENCE BEHIND DRUG COATED BALLOONS OUTCOMES
THE SCIENCE BEHIND DRUG COATED BALLOONS OUTCOMES THE IDEA AND THE TECHNOLOGY FRANCESCO JATTA, PH.D. PROGRAM MANAGER DISCLOSURES I have the following potential conflicts of interest to report: Consulting
More informationTOBA II 12-Month Results Tack Optimized Balloon Angioplasty
TOBA II 12-Month Results Tack Optimized Balloon Angioplasty William Gray, MD System Chief, Cardiovascular Division Main Line Health, Philadelphia, PA Dissection: The Primary Mechanism of Angioplasty Lesions
More informationPHARMACOLOGICAL TREATMENT OF ARTERIAL RESTENOSIS
PHARMACOLOGICAL TREATMENT OF ARTERIAL RESTENOSIS PACLITAXEL VS RAPAMYCIN Paclitaxel essentially freezes the microtubules that are in place during cell division. The cells cannot complete cell division
More informationProspective, randomized controlled study of paclitaxel-coated versus plain balloon angioplasty for the treatment of failing dialysis access
Prospective, randomized controlled study of paclitaxel-coated versus plain balloon angioplasty for the treatment of failing dialysis access Disclosure Speaker name:... I have the following potential conflicts
More informationNon stent based intracoronary drug delivery
Non stent based intracoronary drug delivery Dariusz Dudek Department of Interventional Cardiology Jagiellonian University, Krakow, Poland The European Association of Percutaneous Cardiovascular Interventions
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationRobert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015
Robert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015 Disclosure I have nothing to disclose Randomized Controlled Studies In SFA Technology: What s The Best Tool For
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationThe importance of scientific evidence. Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern
The importance of scientific evidence Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner... I have the following potential
More informationDrug-Coated Balloons: Clinical Role in Coronary and Peripheral Interventional Therapy
Drug-Coated Balloons: Clinical Role in Coronary and Peripheral Interventional Therapy Juan F. Granada, MD Executive Director and Chief Scientific Officer Skirball Center for Cardiovascular Research Cardiovascular
More informationLessons & Perspectives: What is the role of Cryoplasty in SFA Intervention?
Lessons & Perspectives: What is the role of Cryoplasty in SFA Intervention? Michael Wholey, MD, MBA San Antonio, TX USA 19/06/2009 at 09:35 during 4mn as a Speaker Session: Improving Femoral Artery Recanalization
More informationClinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD
Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD Asan Medical Center, Heart Institute, University of Ulsan College of Medicine, Werk et al. Circulation Cardiovasc Intervent 2012
More informationBTK Intervention with Drug- Coated Balloons: Past Lessons and Future Exploration
BTK Intervention with Drug- Coated Balloons: Past Lessons and Future Exploration M Sapoval, C Del Giudice, C Dean Interventional Radiology Dep Hôpital Européen Georges Pompidou APHP, Paris, France IMPORTANT
More informationDrug- Coated Balloons for the SFA: Overview of Technology and Results
Drug- Coated Balloons for the SFA: Overview of Technology and Results NCVH Latin American 2015 Bogota, Colombia April 9-11, 2015 Brian G. DeRubertis, M.D. Associate Professor of Surgery Division of Vascular
More information4/14/2016. Faculty Disclosure. Drug-eluting technology in the SFA and Popliteal. Typical SFA Disease Pattern. Why Peripheral Artery Disease Matters
Drug-eluting technology in the SFA and Popliteal David Paul Slovut, MD, PhD Associate Professor of Medicine and Surgery Co-director of TAVR program Director of Advanced Intervention Faculty Disclosure
More informationEfficacy of DEB in Calcification and Subintimal Angioplasty
Efficacy of DEB in Calcification and Subintimal Angioplasty Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC Div of Cardiovascular Intervention and Research Cardiovascular Center, Korea University
More informationUpdate on the Levant 2 Clinical Trial Programme. Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany
Update on the Levant 2 Clinical Trial Programme Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany Disclosure Speaker name: Dierk Scheinert I have the following potential conflicts of interest
More informationDisclosures. How many people have heard a talk on DCBs? By show of hands, how many people here have used a DCB?
Disclosures Drug Coated Balloons: How they work and what s the evidence? Christopher D. Owens, MD, MSc UCSF vascular surgery I am paid to talk about peripheral interventional procedures by Medtronic and
More informationDCB From a Pre-Clinical Perspective: The Relevance of Paclitaxel Dose and Coating Integrity
DCB From a Pre-Clinical Perspective: The Relevance of Paclitaxel Dose and Coating Integrity Juan Granada, MD President and CEO Cardiovascular Research Foundation Columbia University Medical Center, New
More informationThe Evolution of SFA Treatment Strategy with IN.PACT DCB
The Evolution of SFA Treatment Strategy with IN.PACT DCB JOS VAN DEN BERG, MD OSPEDALE REGIONALE DI LUGANO LUGANO, SWITZERLAND RAPHAEL COSCAS, MD HÔPITAL AMBROISE PARÉ BOULOGNE BILLANCOURT, FRANCE ROBERTO
More informationEvolving Role of Drug-Eluting Stents In Complex SFA - Majestic Trial Data
Evolving Role of Drug-Eluting Stents In Complex SFA - Majestic Trial Data Ralf Langhoff, MD Center for Vascular Medicine Berlin-Wilmersdorf St. Gertrauden Hospital Charité, CC11 Academic Teaching Hospitals
More informationRationale and algorithm for below-the-knee acute gain optimization
Leipzig, 01 Feb. 2018 Rationale and algorithm for below-the-knee acute gain optimization Flavio Airoldi, MD Flavio Airoldi Multimedica IRCCS Milan ITALY flavio.airoldi@multimedica.it Rationale Restenosis
More informationClinical benefits on DES Patient s perspectives
Clinical benefits on DES Patient s perspectives Dr. Skyi Pang Vascular Surgeon Department of Surgery Pamela Youde Nethersole Eastern Hospital Hong Kong Disclosure Speaker name: Skyi Pang... I have the
More informationSirolimus Nanocrystal Balloon Based Delivery for Coronary DES ISR
Sirolimus Nanocrystal Balloon Based Delivery for Coronary DES ISR DR. SAMEER I DANI Director, Department of Cardiology, Apollo Hospital & Life Care Institute (LIMSAR), Ahmedabad, India. IN STENT RESTENOSIS
More informationChristian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide
2-Year Results Of The Tack Optimized Balloon Angioplasty (TOBA) Trial For Fem- Pop Lesions Demonstrates Safety and Efficacy Of The Tack Endovascular System In Repairing Focal Post-PTA Dissections Christian
More informationPaclitaxel-coated versus Plain Balloon Angioplasty in the Treatment of Infrainguinal Vein Bypass Stenosis
Paclitaxel-coated versus Plain Balloon Angioplasty in the Treatment of Infrainguinal Vein Bypass Stenosis T. Hölzenbein, A. Ugurluoglu, M. Aspalter, W. Hitzl, K. Linni Dep Vascular & Endovascular Surgery
More informationILLUMENATE FIH Direct DCB Cohort 12-Month Results
ILLUMENATE FIH Direct DCB Cohort 12-Month Results Stephan Duda Berlin Study Investigators: H. Schröder (PI), B. Lux, F. Rücker, M. Martorana, D. Meyer, H. Hartmann, S. Duda Disclosure Speaker name: S.
More informationLuminor DCB in femoropopliteal lesions
Luminor DCB in femoropopliteal lesions EffPac trial results and solo DCB study design Marcus Thieme, MD Department of Angiology/ Cardiology/ Diabetology Regiomed Vascular Center Sonneberg Clinic for Internal
More informationUpdate from Korea on the Lutonix SFA registry 12 month data
Update from Korea on the Lutonix SFA registry 12 month data Prospective, Multicenter, Post-Market Registy Assessing the Clinical Use and Safety of the Lutonix Drug Coated Balloon in Femoropopliteal Arteries
More informationNeuestes aus der Therapie der pavk. beschichtete Stents + Ballons. Karls-University. Eberhard-Karls. of Tubingen Department of Diagnostic Radiology
Eberhard-Karls Karls-University of Tubingen Department of Diagnostic Radiology Neuestes aus der Therapie der pavk Berlin Dezember 08 beschichtete Stents + Ballons Gunnar Tepe 1 Local Drug Delivery Basic
More informationHow DCB drug dose effects vessel healing. Aloke Finn, MD CVPath Institute Inc. Gaithersburg, MD. USA
How DCB drug dose effects vessel healing Aloke Finn, MD CVPath Institute Inc. Gaithersburg, MD. USA Disclosure Statement of Financial Interest Speaker's name : Aloke, Finn, Gaithersburg I have the following
More informationLocal Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the Leg
original article Local Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the Leg Gunnar Tepe, M.D., Thomas Zeller, M.D., Thomas Albrecht, M.D., Stephan Heller, M.D., Uwe Schwarzwälder,
More informationNew Data to Shape the Era of Drug Elution in Peripheral Interventions
New Data to Shape the Era of Drug Elution in Peripheral Interventions William A. Gray MD Director of Endovascular Services Columbia University Medical Center New York Lower Extremity Endovascular - Interventions
More informationLessons learnt from DES in the SFA is there any ideal concept so far?
Wednesday, January 25, 2017 - Time: 11:49-11:55 DEEP DIVE SESSION: Lower limb interventions (part II) Lessons learnt from DES in the SFA is there any ideal concept so far? S.Müller-Hülsbeck, MD, EBIR,
More informationLatest Insights from the LEVANT II study and sub-group analysis
Latest Insights from the LEVANT II study and sub-group analysis Prof. Dr. med. Dierk Scheinert Division of Interventional Angiology University-Hospital Leipzig, Germany Conflicts of Interest Advisory Board
More informationThe Lutonix BTK Clinical Trial Programme: Status Update and Real World Clinical Experience
The Lutonix BTK Clinical Trial Programme: Status Update and Real World Clinical Experience Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany Disclosure Speaker name: Dierk Scheinert I have
More informationKlinikum Rosenheim Department of Diagnostic and Interventional Radiology
Klinikum Rosenheim Department of Diagnostic and Interventional Radiology Is Directional Atherectomy (Silverhawk Or Turbohawk) With DEB, Better Than DEB Alone: Based On The DEFINITIVE AR RCT: 1-Year Results
More informationUpdate on the OPTIMIZE BTK Trial. Marianne Brodmann, MD Division of Angiology Medical University Graz, Austria
Update on the OPTIMIZE BTK Trial Marianne Brodmann, MD Division of Angiology Medical University Graz, Austria Disclosure Speaker name: Marianne Brodmann, MD... I have the following potential conflicts
More informationFuture Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit?
Future Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit? John R. Laird Adventist Heart and Vascular Institute St. Helena, CA Disclosure Speaker name: John R. Laird... I have
More informationDrug eluting balloons in CAD
Drug eluting balloons in CAD Ioannis Iakovou, MD, PhD Interventional Cardiology 1 st Cath Lab Onassis Cardiac Surgery Center Drug-Eluting Balloons (DEB) Technology and Applications 1. Special Features
More informationAre Drug-coated balloons Durable? Level 1 evidence review. Koen Keirse, MD Vascular Surgery, RZ Tienen Tienen, Belgium
Are Drug-coated balloons Durable? Level 1 evidence review Koen Keirse, MD Vascular Surgery, RZ Tienen Tienen, Belgium Disclosure Speaker name: Koen Keirse, MD I have the following potential conflicts of
More informationNext Generation of DCB: Efficacy and tolerance of drug-coated hyper-compliant balloons (DCHCB) in peripheral arteries of swine
Next Generation of DCB: Efficacy and tolerance of drug-coated hyper-compliant balloons (DCHCB) in peripheral arteries of swine Maciej Kusmierczuk 1 ; Stephanie Bienek, PhD 1 ; Sebastian Schurmann 1 ; Antje
More informationThere are multiple endovascular options for treatment
Peripheral Rotablator Atherectomy: The Below-the-Knee Approach to Address Calcium Head On Peripheral Rotablator s front-cutting, diamond-tipped burr provides stable rotation in calcified lesions. BY SONYA
More informationDrug-coated balloons in BTK:
Drug-coated balloons in BTK: Where do we stand and what are the open questions? Dr. Marc Bosiers LINC 2019 - Leipzig My disclosures x o I do not have any potential conflicts of interest to report o I have
More informationIN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014
IN-STENT RESTENOSIS K.Boerlage-van Dijk CarVasZ 2014 Definition ISR Angiographic: recurrent diameter stenosis >50% at the stent segment or edges (5-mm segments adjacent to stent) Mehran system morphological
More informationPERFORMANCE YOU CAN TRUST. EverFlex Self-expanding Peripheral Stent with Entrust Delivery System
PERFORMANCE YOU CAN TRUST EverFlex Self-expanding Peripheral Stent with Entrust Delivery System The Entrust Delivery System is designed to provide improved patient outcomes and procedural efficiency. The
More informationSuperficial Femoral Artery Intervention: The gift that keeps on giving! Wm. Britton Eaves,MD WKHSC Bossier City, LA
: The gift that keeps on giving! Wm. Britton Eaves,MD WKHSC Bossier City, LA Peripheral arterial disease (PAD) of the superficial femoral artery (SFA) is the most common cause of intermittent claudication
More informationDrug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2
Drug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2 Raban V. Jeger,Ahmed Farah, Marc-Alexander Ohlow, Norman Mangner, Sven Möbius-Winkler, GregorLeibundgut, Daniel Weilenmann, JochenWöhrle,
More informationThe SeQuent Please drug-coated balloon system for percutaneous transluminal coronary angioplasty
Device Evaluation The SeQuent Please drug-coated balloon system for percutaneous transluminal coronary angioplasty Endovascular therapy for treatment of arterial obstructions has emerged as one of the
More informationUpdate on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria
Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee Marianne Brodmann, MD Medical University Graz Graz, Austria Critical Limb Ischemia Infrapopliteal arterial disease is a leading source
More informationUtility of Image-Guided Atherectomy for Optimal Treatment of Ambiguous Lesions by Angiography
Utility of Image-Guided Atherectomy for Optimal Treatment of Ambiguous Lesions by Angiography Jon C. George, MD; Vincent Varghese, DO From the Deborah Heart and Lung Center, Browns Mills, New Jersey. ABSTRACT:
More informationUpdate on the role of drug eluting balloons
Update on the role of drug eluting balloons William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular Research
More informationThe Utility of Atherectomy and the Jetstream Atherectomy System
The Utility of Atherectomy and the Jetstream Atherectomy System William A. Gray, MD Columbia University Medical Center 2014 Boston Scientific Corporation or its affiliates. All rights reserved. IMPORTANT
More informationOutcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry
Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry Marianne Brodmann, MD Head of the Clinical Division of Angiology Department of Internal Medicine Medical University
More informationDrug Elution, Data, and Decisions
Drug Elution, Data, and Decisions What the data tell us about how to integrate drug-eluting technology into our daily practice. BY GARY ANSEL, MD, AND JOHN A. PHILLIPS, MD The use of drug-eluting technology
More informationPromise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD
Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD Associate Professor of Vascular Surgery University of New South Wales Sydney,
More informationDEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.
DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the
More informationINTERVENTIONAL VASCULAR DIAGNOSTICS AND THERAPY. SeQuent Please OTW PERIPHERAL DRUG COATED BALLOON CATHETER
INTERVENTIONAL VASCULAR DIAGNOSTICS AND THERAPY SeQuent Please OTW PERIPHERAL DRUG COATED BALLOON CATHETER SeQuent Please OTW PERIPHERAL DRUG COATED BALLOON CATHETER The next level in treating peripheral
More informationBioabsorbable Scaffolding: Technology and Clinical Update. PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland
Bioabsorbable Scaffolding: Technology and Clinical Update PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland Disclosures I am not Ron Waksman 1 Clinical experience with AMS
More informationIs a Stent or Scaffold Necessary in The SFA?
1 2 3 Is a Stent or Scaffold Necessary in The SFA? Stents were developed to optimize acute results after angioplasty Specifically, stents are universally accepted to manage flow limiting dissections and
More information6-month 0utcomes of a Novel Sirolimus Coated DCB Technology Evaluated in SFA Thomas Zeller, MD University Heart Center Freiburg-Bad Krozingen
First Report of the SELUTION Trial: 6-month 0utcomes of a Novel Sirolimus Coated DCB Technology Evaluated in SFA Thomas Zeller, MD University Heart Center Freiburg-Bad Krozingen On behalf of the SELUTION
More informationStellarex Drug-coated 0.035" Angioplasty Balloon. Featuring EnduraCoat Technology. The Clear DCB Choice
Stellarex Drug-coated 0.035" Angioplasty Balloon Featuring EnduraCoat Technology The Clear DCB Choice Top-tier outcomes with the lowest therapeutic drug dose in all patients common to complex 89.0 % patency
More informationThe latest generation DEB
The latest generation DEB V. Riambau, MD. PhD Prof. and Chief of Vascular Surgery Division, Cardiovascular Institute, Hospital Clínic of Barcelona University of Barcelona Consultant: Bolton Medical/ Medtronic/
More informationVessel Preparation: What does it mean and what are the current tools? Lawrence Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA
Vessel Preparation: What does it mean and what are the current tools? Lawrence Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA Disclosure Statement of Financial Interest Within the past 12 months,
More information12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort. Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany
12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany Disclosure Speaker name: Gunnar Tepe I have the following potential conflicts
More informationMerits and demerits of DES, DEB or covered stent in lower extremity arterial occlusive disease 성균관의과대학삼성서울병원순환기내과최승혁
Merits and demerits of DES, DEB or covered stent in lower extremity arterial occlusive disease 성균관의과대학삼성서울병원순환기내과최승혁 Contents DES in SFA DES in BTK DEB in SFA DEB in BTK Current status of covered stent
More information5-YEAR SUPERIOR RESULTS. Compared to PTA and Zilver BMS 1. NOW WITH 140 mm LENGTH STENTS
SUPERIOR 5-YEAR RESULTS Compared to PTA and Zilver BMS 1 NOW WITH 140 mm LENGTH STENTS 1. Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal
More informationDCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes
DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes Carlos Mena, MD FACC FSCAI Associate Professor of Medicine - Cardiology Director Cardiac
More informationMichael K.W. Lichtenberg, MD
Ranger All-Comer Registry Treatment of femoropopliteal atherosclerotic lesions using the Drug eluting Balloon Ranger: An All Comers Registry Michael K.W. Lichtenberg, MD Klinikum Arnsberg Arnsberg, Germany
More informationWhich Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA
Which Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA Brian DeRubertis, MD, FACS Associate Professor of Surgery UCLA Division
More informationClinically proven. ordering info. Vascular Intervention // Peripheral Self-Expanding Stent System/0.018 /OTW. Pulsar-18
140 μm thin struts Clinically proven 4F low profile Vascular Intervention // Peripheral Self-Expanding Stent System/0.018 /OTW Pulsar-18 Technical data / ordering info 140 μm thin struts - thinner than
More informationDrug-Eluting Balloon Angioplasty for Carotid In-Stent Restenosis
J ENDOVASC THER 2012;19:729 733 729 CASE REPORT Drug-Eluting Balloon Angioplasty for Carotid In-Stent Restenosis Francesco Liistro, MD 1 ; Italo Porto, MD, PhD 1 ; Simone Grotti, MD 1 ; Giorgio Ventoruzzo,
More informationCOMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions. Dierk Scheinert
COMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions Dierk Scheinert Department of Angiology University Hospital Leipzig, Germany Disclosure
More informationThe Role of Lithotripsy in Solving the Challenges of Vascular Calcium. Thomas Zeller, MD
The Role of Lithotripsy in Solving the Challenges of Vascular Calcium Thomas Zeller, MD 1 1 Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: X X
More informationDESIGN GOALS AND PRE- CLINICAL EVIDENCE OF NEXT GENERATION DCB
DESIGN GOALS AND PRE- CLINICAL EVIDENCE OF NEXT GENERATION DCB Juan F. Granada, MD Executive Director and Chief Scientific Officer CRF-Skirball Center for Innovation Columbia University Medical Center,
More informationDRUG-COATED BALLOONS AND CORONARY BIFURCATION LESIONS
DRUG-COATED BALLOONS AND CORONARY BIFURCATION LESIONS *Alessandro Durante, 1 Pietro Leonida Laforgia 2 1. Ospedale Valduce, Como, Italy 2. Università degli Studi di Milano, Milan, Italy *Correspondence
More informationCurrent Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis
Current Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis Osamu Iida, MD From the Kansai Rosai Hospital Cardiovascular Center, Amagasaki City, Japan. ABSTRACT: Approximately
More informationMaximizing Outcomes in a complex population with Drug-coated balloon
Maximizing Outcomes in a complex population with Drug-coated balloon March 13, 2018 Chumpol Wongwanit, MD Siriraj Hospital, Mahidol University, Bangkok, Thailand LINC Asia-Pacific 2018, Hong Kong Disclosure
More informationMICHAEL R. JAFF, DO MASSACHUSETTS, UNITED STATES. Medtronic Further. Together
DRUG-COATED BALL0ON TREATMENT FOR PATIENTS WITH INTERMITTENT CLAUDICATION: INSIGHTS FROM THE IN.PACT GLOBAL FULL CLINICAL COHORT MICHAEL R. JAFF, DO MASSACHUSETTS, UNITED STATES Medtronic Further. Together
More informationFabrizio Fanelli, MD, EBIR Director Vascular and Interventional Radiology Department "Careggi " University Hospital Florence - Italy
Don t Use Risky and Embolizing Drug Coated Balloons Below The Knee! Fabrizio Fanelli, MD, EBIR Director Vascular and Interventional Radiology Department "Careggi " University Hospital Florence - Italy
More informationThe Effect of Paclitaxel Drug-coating on the Balloon Performances
International Conference on Manufacturing Science and Engineering (ICMSE 2015) The Effect of Paclitaxel Drug-coating on the Performances Shi Xiao Man1,2,a, Lu Chun Lan1,b and Li Xin Yue1,2,c* 1 College
More informationCurrent Status of Drug-Eluting Stents and Drug-Eluting Balloons for the Superficial Femoral Artery
Curr Surg Rep (2013) 1:90 97 DOI 10.1007/s40137-013-0018-x ENDOVASCULAR TREATMENT OF COMPLEX VASCULOPATHIES (BG DERUBERTIS, SECTION EDITOR) Current Status of Drug-Eluting Stents and Drug-Eluting Balloons
More informationCould a combination of DCB + stent be the answer in complex SFA lesions
Could a combination of DCB + stent be the answer in complex SFA lesions Sven Bräunlich, MD Division of Interventional Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich
More informationCombine the best of both worlds
S c i e n c e B a s e d E v o l u t i o n s l e a d t o R e v o l u t i o n a r y S o l u t i o n s PIONEER CoCr STENT ON DEB Combine the best of both worlds A next step in cardiovascular treatment should
More informationDepartment of Radiology. EffPac - Trial:
Department of Radiology EffPac - Trial: Effectiveness of LUMINOR DCB versus POBA in the SFA: primary endpoint and 6 months results Ulf Teichgräber on behalf of the Investigators NCT02540018 Teichgräber
More informationImportance of Thorough Vessel Preparation Followed By Anti- Restenotic Therapy: An Update from the DEFINITIVE AR Study
Importance of Thorough Vessel Preparation Followed By Anti- Restenotic Therapy: An Update from the DEFINITIVE AR Study Gunnar Tepe, MD Romed Klinikum, Rosenheim, Germany On behalf of the DEFINITIVE AR
More informationDrug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort
Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort a.o. Univ. Prof. Dr. Marianne Brodmann Medical University of Graz Graz,
More informationSession: DEB their Utility. Innovation in Drug Coated Balloons
Session: DEB their Utility 2 nd MARCH 2014 Innovation in Drug Coated Balloons Dr. Upendra Kaul Fortis Escorts Heart Institute New Delhi Disclosure I, Upendra Kaul, do not have a financial interest/arrangement
More informationMaking BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD
Making BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD Faculty Disclosure Thomas Zeller, MD For the 12 months preceding this presentation, I disclose the following types of
More informationAlternative concepts for drug delivery in BTK arteries the LIMBO project
Alternative concepts for drug delivery in BTK arteries the LIMBO project Dierk Scheinert, MD Division of Interventional Angiology University Hospital Leipzig, Germany 1 Disclosure Speaker s name: Dierk
More informationThe role of bioabsorbable stents in the superficial femoral artery What is going on? Frank Vermassen Ghent University Hospital Belgium
The role of bioabsorbable stents in the superficial femoral artery What is going on? Frank Vermassen Ghent University Hospital Belgium Disclosures Speaker name: Frank Vermassen I have the following potential
More informationInterventional Radiology in Peripheral Vascular Disease: How Far Can We Go? Dr. L. F. CHENG Department of Radiology Princess Margaret Hospital
Interventional Radiology in Peripheral Vascular Disease: How Far Can We Go? Dr. L. F. CHENG Department of Radiology Princess Margaret Hospital History The era of innovation in image-guided intervention
More informationA New Treatment Paradigm Outside-In
A New Treatment Paradigm Outside-In 2 2013 Mercator MedSystems OneMedForum Jan 8, 2013 Outside-In Response: Signal Amplification Signal convection Signal amplification Modified from Michel 2007, ATVB 3
More informationDo we really need a stent in long SFA lesions? No: DEB is the answer
Do we really need a stent in long SFA lesions? No: DEB is the answer Thomas Zeller, MD University Heart-Center Freiburg-Bad Krozingen Bad Krozingen Germany My Disclosures: Advisory Board: Medtronic-Invatec,
More informationDEB in Periphery: What we Know Till Now
DEB in Periphery: What we Know Till Now Karl-Ludwig Schulte Vascular Center Berlin Ev. Hospital Königin Elisabeth St. Gertrauden Hospital Charité, CC13, Humboldt-University Berlin www.vascular-center-berlin.com
More informationBIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort
BIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort Prof. Dr. Gunnar TEPE, Klinikum Rosenheim, Germany CCI on behalf of the BIOLUX P-III Investigators Disclosure
More informationRecurrent lesions in AV access & Initial DCB experience in India
Recurrent lesions in AV access & Initial DCB experience in India Dr. Virender K Sheorain Consultant Interventional Radiologist Medanta-The Medicity Hospital Gurgaon, INDIA Disclosure Speaker name:... I
More information